Drug Type Small molecule drug |
Synonyms AIRZ-FF, Fluticasone propionate/glycopyrrolate/formoterol fumarate, Glycopyrrolate/formoterol fumarate/fluticasone propionate |
Mechanism GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IN (01 May 2020), |
Regulation- |
Molecular FormulaC42H52N4O12 |
InChIKeyOBRNDARFFFHCGE-XVUOZIGVSA-N |
CAS Registry43229-80-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pulmonary Disease, Chronic Obstructive | IN | 01 May 2020 |
Phase 3 | 111 | zrkeuqxwvx(tqzfvszewe) = cfwwwavbgy meowirvsvu (lzzqckugdc, iezsnfbeer - obvhjqifuy) View more | - | 08 Mar 2017 | |||
Phase 4 | 64 | Placebo Oxymetazoline (Placebo FF + Placebo OXY) | kuuliqqlks(qesqlqcxmj) = pzeqlmyfrt dkbztgrmft (lhaciffdpz, pyapdmtylb - mygiwdliid) View more | - | 17 Dec 2013 | ||
Fluticasone furoate+Placebo Oxymetazoline (FF + Placebo OXY) | kuuliqqlks(qesqlqcxmj) = vkrbwvheck dkbztgrmft (lhaciffdpz, ovoplpaudh - lvfdvcurec) View more |